Phillip Darragh
Foot Surgery · Redondo Beach, CANPI 1922044908
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,569 of the $2,054 with a category attached, or 76.4%. 9 manufacturers reported payments, led by Paragon 28, Inc. at 37.2% of the total. Reporting peaked in 2019 at $946 and has fallen 87.1% since, to $122 in 2025.
Across 26 payments — averaging $79.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paragon 28, Inc.$765
- Cardiovascular Systems Inc.$406
- Amgen$342
- In2bones USA, LLC$168
- Johnson & Johnson$134
- Stryker$115
- plus $124 from 3 others
What the payments were for
- Travel & lodging$48524%
- Food & beverage$1,56976%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paragon 28, Inc. | 3 | $765 |
| Cardiovascular Systems Inc. | 4 | $406 |
| Amgen(2 entities) | 3 | $342 |
| In2bones USA, LLC | 2 | $168 |
| Johnson & Johnson | 7 | $134 |
| Stryker | 4 | $115 |
| Angiodynamics, Inc. | 1 | $96 |
| Integra Lifesciences Corporation | 1 | $16 |
| Sandoz | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,054 in reported general payments places this provider in the 75th percentile of 71 foot surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CiclopiroxCiclopirox Olamine | 147 | $2,638 |
| Ciclopirox | 44 | $1,057 |
| Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort | 17 | $837 |
| Gabapentin | 38 | $411 |
| Terbinafine Hcl | 27 | $406 |
| Cephalexin | 49 | $289 |
| Ketoconazole | 13 | $233 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $153 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $83 |
| Methylprednisolone | 14 | $58 |
| Meloxicam | 16 | $15 |
Paid to pharmacies, not to this prescriber.
Other foot surgery in Redondo Beach
- Helen KuoRedondo Beach$796
- Alexander ReyzelmanSan Francisco$137K
- Helen ShnolBeverly Hills$22K
- Benedict ChingFountain Valley$19K
- Zachary KramerEncinitas$14K
- Tara HarringtonElk Grove$12K
- Jack MorganMonterey Park$11K
- Jaehyun KimSunnyvale$7K
- Ingrid EdelmanSan Diego$6K
- Spencer SterlingBellflower$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.